Supplementary Table 3. EPO (Erythropoietin)
Author, Year PMID, Title Model Donor
site Recipient site LOE Technique Follow-up Result Conc
Animal Studies
Hamed, 2010
21085572 Erythropoietin improves
the survival of fat tissue after its transplantation
in nude mice [25]
Nude mice
Human
thigh Scalp 5
Experimental: low- dose EPO + fat graft
(n=10) Experimental: high- dose EPO + fat graft
(n=10) Control: VEGF + fat
graft (n=10) Control: PBS + fat
graft (n=10)
15 weeks
The weight and volume of EPO- treated grafts were
higher than PBS-treated and VEGF- treated grafts.
EPO treatment increased the expression of microvascul ar density and angiogenic factors,
while reducing inflammatio n and fat cell
apoptosis in a dose- dependent manner
+
Human Studies
Sabbatini, 2016 5042341, Erythropoietin stimulation of human
adipose tissue for therapeutic refilling releases
protective cytokines [53]
Human 8 women during reconstructi
ve procedures
N/A 2 Group 1: EPO-treated group Group 2: LPS-treated
group Control group: no
treatment
NA EPO-treated group showed less inflammatory factors and
more reparative factors than other groups.
+
Sabbatini, 2015
26034645 Effects of erythropoietin
on adipose tissue: a possible strategy in
refilling [54]
In vitro Anterior mid- face
N/A 5
Fat graft was seeded on culture dishes for 24 hours and then treated for 3 weeks
with either 0.15 μg/ml of EPO, 0.30 μg/ml of EPO, or 0.60
μg/ml of EPO. After staining with CD31
and CD68, quantification of cell
infiltration in fat grafts was estimated.
3 weeks
EPO
increased the number of CD31- positive microvessel s and
CD31- positive small lymphocyte s in the fat grafts. EPO decreased the
number of CD68- positive cells and macrophage s in the fat
grafts. +
